BRCA mutation

#VisualAbstract: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to placebo. 2. The majority of adverse events reported in the olaparib group were low-grade. Among high-grade adverse events, anemia and neutropenia were the most common. Evidence Rating Level: 1 (Excellent)       Czytaj więcej…

BRCA mutation

The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer

1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to placebo. 2. The majority of adverse events reported in the olaparib group were low-grade. Among high-grade adverse events, anemia and neutropenia were the most common. Evidence Rating Level: 1 Czytaj więcej…